A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding

Drug Discovery Today

Volumn 12, Issue 15-16, 2007, Pages 622-633

  Bogoyevitch, Marie A ^a,b   Fairlie, David P ^c  

^a School of Biomedical Biomolecular and Chemical Sciences   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AAL 993; ADENOSINE TRIPHOSPHATE; AG 538; ANTHRANILIC ACID DERIVATIVE; BMS 345541; DORAMAPIMOD; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B KINASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ON 012380; ON 01910; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SORAFENIB; THIADIAZOLE DERIVATIVE; THIADIAZOLIDINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING SITE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; DIABETES MELLITUS; DRUG TARGETING; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE COMPLEX; HUMAN; NONHUMAN; PROTEIN INTERACTION; REVIEW;

ADENOSINE TRIPHOSPHATE; BINDING SITES; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES;

EID: 34547817154     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.06.008     Document Type: Review

References (60)

1. Manning G., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
2. Fischer P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem. 11 (2004) 1563-1583
3. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91 (2004) 1-30
4. Wong S., and Witte O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22 (2004) 247-306
5. Noble M.E., et al. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
6. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
7. Nagar B., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
8. Mol C.D., et al. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Dev. 7 (2004) 639-648
9. Pargellis C., et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9 (2002) 268-272
10. Regan J., et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45 (2002) 2994-3008
11. Regan J., et al. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J. Med. Chem. 46 (2003) 4676-4686
12. Regan J., et al. The kinetics of binding to p38MAP kinase by analogues of BIRB 796. Bioorg. Med. Chem. Lett. 13 (2003) 3101-3104
13. Lee M.R., and Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem. 12 (2005) 2979-2994
14. Kuma Y., et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280 (2005) 19472-19479
15. Sullivan J.E., et al. Prevention of MKK6-dependent activation by binding to p38α MAP kinase. Biochemistry 44 (2005) 16475-16490
16. Gill A.L., et al. Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48 (2005) 414-426
17. Wilhelm S., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (2006) 835-844
18. Wan P.T., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
19. Wilhelm S.M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
20. Adnane L., et al. Sorafenib (BAY 43-9006, Nexavar((R))), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407 (2005) 597-612
21. Hahn O., and Stadler W. Sorafenib. Curr. Opin. Oncol. 18 (2006) 615-621
22. Manley P.W., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697 (2004) 17-27
23. Favata M.F., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273 (1998) 18623-18632
24. Sebolt-Leopold J.S., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5 (1999) 810-816
25. Ohren J.F., et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11 (2004) 1192-1197
26. Han S., et al. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 5467-5473
27. Davidson W., et al. Discovery and characterization of a substrate selective p38α inhibitor. Biochemistry 43 (2004) 11658-11671
28. Barnett S.F., et al. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem. 5 (2005) 109-125
29. Castillo S.S., et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res. 64 (2004) 2782-2792
30. Yang L., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64 (2004) 4394-4399
31. Lindsley C.W., et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 761-764
32. Barnett S.F., et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385 (2005) 399-408
33. Zhao Z., et al. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 905-909
34. DeFeo-Jones D., et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 4 (2005) 271-279
35. Martinez A., et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45 (2002) 1292-1299
36. Martinez A., et al. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J. Med. Chem. 48 (2005) 7103-7112
37. Conde S., et al. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J. Med. Chem. 46 (2003) 4631-4633
38. Burke J.R., et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J. Biol. Chem. 278 (2003) 1450-1456
39. McIntyre K.W., et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 48 (2003) 2652-2659
40. Herrmann O., et al. IKK mediates ischemia-induced neuronal death. Nat. Med. 11 (2005) 1322-1329
41. Yang J., et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 12 (2006) 950-960
42. Adrian F.J., et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2 (2006) 95-102
43. Hancock C.N., et al. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J. Med. Chem. 48 (2005) 4586-4595
44. Heo Y.S., et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23 (2004) 2185-2195
45. Barr R.K., et al. The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J. Biol. Chem. 279 (2004) 36327-36338
46. Barr R.K., et al. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277 (2002) 10987-10997
47. Gumireddy K., et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7 (2005) 275-286
48. Strebhardt K., and Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6 (2006) 321-330
49. Gumireddy K., et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1992-1997
50. Levitzki A., and Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Ann. Rev. Biochem. 75 (2006) 93-109
51. Blum G., et al. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J. Biol. Chem. 278 (2003) 40442-40454
52. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315 (2005) 971-979
53. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 312 (2006) 1175-1178
54. Wood E.R., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2004) 6652-6659
55. Rishton G.M. Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations. Med. Chem. 1 (2005) 519-527
56. Davies S.P., et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
57. Bain J., et al. The specificities of protein kinase inhibitors: an update. Biochem. J. 371 (2003) 199-204
58. Fabian M.A., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
59. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
60. Frembgen-Kesner T., and Elcock A.H. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. J. Mol. Biol. 359 (2006) 202-214